Stock comparison
Cytek Biosciences
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CTKB
Cytek Biosciences
Market cap
$517.86M
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CTKB | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 21F | 75B | IDXX |
| Benjamin Graham | 35D | 80A | IDXX |
| Philip Fisher | 30F | 75B | IDXX |
| Peter Lynch | 22F | 71B | IDXX |
| Joel Greenblatt | 0F | 83C | IDXX |
| Charlie Munger | 21F | 87A | IDXX |
| Terry Smith | 23F | 84A | IDXX |
Side-by-side metrics
| Metric | CTKB | IDXX |
|---|---|---|
| Market cap | $517.86M | $44.12B |
| P/E (TTM) | - | 39.0x |
| EV/EBIT | - | 31.6x |
| ROIC (TTM) | -11.42% | 40.66% |
| Gross margin | 51.7% | 62.05% |
| Net margin | -36.25% | 24.63% |
| Revenue CAGR 5y | 12.02% | 7.56% |
| EPS CAGR 5y | - | 10.79% |
| Debt / Equity | 0.1x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CTKB leads on
- EV/EBIT-vs 31.6x+139%
- P/E (TTM)-vs 39.0x+118%
- Debt / Equity0.1xvs 0.7x+84%
- Revenue CAGR 5y12.02%vs 7.56%+37%
IDXX leads on
- Net margin24.63%vs -36.25%+168%
- ROIC (TTM)40.66%vs -11.42%+128%
- Market cap$44.12Bvs $517.86M+99%
- Gross margin62.05%vs 51.7%+17%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.